Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-1905 injection approved for clinical trials.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, its subsidiary Guangdong Jiangsu Hengrui Pharmaceuticals Co., Ltd. has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration ("NMPA") regarding SHR-1905 injection, and will soon start clinical trials. SHR-1905 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody that can block the release of inflammatory cytokines, suppress the transmission of downstream inflammatory signals, ultimately improve the inflammatory state, and control disease progression. Currently, a similar product Tezepelumab (AstraZeneca/Amgen, trade name Tezspire) has been approved for sale globally, with estimated global sales of Tezspire in 2024 to be around 1.22 billion US dollars, according to the EvaluatePharma database. As of now, the accumulated research and development investment for the SHR-1905 injection project is approximately 209.62 million yuan.